Melanonychia tends to persist, except when it is related to medication in which case it fades following its withdrawal.
Ultimately, the decision to continue, adjust, or switch therapy should be made collaboratively between the patient and their healthcare team, taking into account individual circumstances, treatment goals, and the overall risk-benefit profile
BPC-157 BPC-157
Recently, some companies have been hyping the practice of microdosing compounded GLP-1 weight loss medications meaning taking a much smaller dose than the amount approved by the FDA
(Hunterbrook Media, the editorial affiliate of hedge fund Hunterbrook Capital, recently conducted an investigation into Hims & Hers Healths entry into the GLP-1 market, and one of its employees was offered compounded GLP-1 meds without their BMI being verified
Soltani S, Abdollahi S, Aune D, Jayedi A (2021) Body mass index and cancer risk in patients with type 2 diabetes: a doseresponse meta-analysis of cohort studies